Leading Point-of-Care Health Information Network with National Clinic & Pharmacy Coverage

Valuation: CA$642,000

Revenue: CA$2,972,818

EBITDA: CA$1,283,948

Year Established: 1991

This Canadian company is the country’s leading point-of-care (POC) health information network, with a footprint spanning 3,200+ medical and pharmacy locations nationwide. With more than 30 years of expertise, it has built a reputation as the partner of choice for pharmaceutical brands and health associations, delivering trusted, compliant, and impactful communications directly at the point of care.

The business has consistently achieved EBITDA margins above 40%, driven by strong recurring revenues, exceptional client loyalty, and a lean operating model. Even during the COVID downturn, it sustained revenues through its subscription-based packages and expanded its reach, demonstrating resilience and operational strength.

Now positioned as the dominant POC player in Canada, the company offers exclusive access to clinic and pharmacy networks, a growing digital presence, and clear opportunities to expand into specialty healthcare segments. With strong industry tailwinds, significant upside exists through digital innovation, AI-enabled engagement, and broader service expansion, making this a rare opportunity to acquire a profitable, scalable, and defensible platform.

Key Figures

Status:

Live

Valuation:

CA$642,000

Revenue:

CA$2,972,818

EBITDA:

CA$1,283,948

EBITDA Multiple:

5x

Year Established:

1991

Location:

Canada

NDA Signature

Portfolio Name

Mutual Non-Disclosure Agreement

Mutual Non-Disclosure Agreement
	
This non-disclosure agreement (“Agreement”) is between the parties signing below, and covers past, current and future discussions and presentations for the Purpose set out below. 

Company Name:  Capital A Group Ltd
Address: 13 Hanover Sq, London , W1S 1HN
Signature: 

Print Name:  ANDY DAY
Title: CEO
Date:  10/03/2025

AND details provided by this electronic form

1. 	Definitions 
In this Agreement the following terms have the following meanings:

“Confidential Information” is non-public information, whether in verbal, visual or physical form, such as trade secrets, specifications, know-how, designs, drawings, plans, strategies, illustrations, marketing data, marketing campaigns, product concepts, databases, customer lists, sales data, sales prices, software, algorithms and other related business information.

“Representatives” means the relevant party’s employees, contractors, consultants and advisers.

“Disclosing Party” means the party who discloses Confidential Information whether directly or indirectly.

“Receiving Party” means the party who receives Confidential Information whether directly or indirectly.


2.	Confidential Information
2.1	Purpose of this Agreement – In consideration of the provision of Confidential Information by or on behalf of each party, this Agreement allows each party to disclose Confidential Information to the other for the Purpose. 

2.2 	General Obligation – The Receiving Party shall treat all Confidential Information received as strictly confidential.

2.3 	Not Included – Information that would otherwise be considered Confidential Information is not Confidential Information if:

a. 	obtained from another source who can prove lawfully that they can disclose the information and is not under obligation to keep it confidential; 

b. 	it is, or becomes publicly available through no fault of the Receiving Party;

c.	known to the Receiving Party at the time of disclosure and not obtained directly or indirectly from the Disclosing Party; or

d.	it is independently developed by the Receiving Party.

2.4	Protection and Use – The Receiving Party must:
a. 	only use the Confidential Information to carry out the Purpose;

b. 	subject to clause 2.5, disclose the Confidential Information to its Representatives who have a justifiable “need-to-know” which involves the Purpose;

c. 	not reverse engineer, or (where applicable) de-encrypt Confidential Information of a technical nature; and/or

d. 	not reproduce or adapt the Confidential Information without the Disclosing Party’s prior written Agreement. 

2.5  	Disclosure to Representatives – Before disclosing Confidential Information to its Representatives, the Receiving Party must: 

a. 	ensure that all Representatives are aware of the obligations of this Agreement;

b. 	ensure Representatives agree to the terms of this Agreement in writing; and

c. 	make all such Representatives aware that the Receiving Party will take any necessary action against any Representatives who breach the obligations of this Agreement. 

3.	No accuracy as to Confidential Information
No warranty or representation is or will be given, by either party, whether express or implied, as to the accuracy and/or completeness of the Confidential Information or that its use will not infringe any third party’s rights.  The Receiving Party acknowledges that it will be its responsibility to verify the accuracy and/or completeness of the Confidential Information to its own satisfaction.  No right or licence is granted to the Receiving Party in relation to the Confidential Information other than as expressly set out in this Agreement. 

4.	Indemnity
The Receiving Party shall indemnify the Disclosing Party and keep the Disclosing Party indemnified against any losses, damages and liabilities suffered by it arising from a failure by the Receiving Party to comply with the terms of this Agreement.

5.	Legal compulsion to disclose Confidential Information.
Either party may disclose Confidential Information if required to comply with a court order or other government demand that has the force of law.  Before doing so the Receiving Party must give immediate notice to the Disclosing Party so that they have the opportunity to seek a protective order or other appropriate solution. If the Disclosing Party is unable to gain the protective order or appropriate solution then the Receiving Party must only disclose that portion of the Confidential Information that is necessary to comply with its obligations. The Receiving Party shall use all reasonable endeavours to obtain any appropriate court order or other reliable assurance that the Confidential Information will remain confidential.

6.	No Rights Granted
The disclosure of Confidential Information pursuant to this Agreement shall not be construed as granting to or conferring upon the Receiving Party  by licence or otherwise, express or implied, any patent, trade mark, copyright, database right, design right, know how, trade secrets or any other intellectual property rights of the Disclosing Party. Nothing in this Agreement, nor any discussions that take place pursuant to this Agreement, expressly or impliedly obligates or is a commitment by either party to enter into any business relationship or any agreement of any kind with the other.

7.	Duration
7.1	This Agreement shall be effective on the date when this Agreement is signed by both parties, or when the first Confidential Information is disclosed, whichever occurs first. The obligations of each Party shall survive for 3 years from the date on which the Confidential Information is disclosed. 

7.2	At the request of the Disclosing Party, the Confidential Information disclosed including all copies of it shall be immediately returned to the Disclosing Party or destroyed by the Receiving Party. 

8.	Injunctive Relief
Without prejudice to any other rights or remedies that either party may have, each acknowledges and agrees that either will, without proof of special damage, be entitled to an injunction, specific performance or other equitable relief for any threatened or actual breach of the provisions of this Agreement, in addition to any damages or other remedy to which either may be entitled.

9.	Governing Law and Jurisdiction
This Agreement and any disputes arising out of or in connection with it (whether contractual or non-contractual such as claims in tort, breach of statute or regulation, or otherwise), shall be construed in accordance with and governed exclusively by the laws of England and Wales.  Any and all disputes or litigation between the parties arising under this Agreement whatever the cause of action shall be conducted exclusively in the courts of England and Wales.

10.	Entire Agreement
This Agreement contains the entire agreement between the parties. It replaces any previous understandings or agreements, regarding Confidential Information disclosed for the Purpose. The terms of this Agreement may only be varied by written agreement of the parties.

Checkboxes

I have read through the Mutual Non-Disclosure Agreement

If you are human, leave this field blank.

Revenue (USD)

EBITDA (USD)

Revenue Source (%)

Retainer: 50%

Project: 50%

Service Source (%)

Point-of-care Advertising programs: 90%

Custom Projects & Research: 10%

Client Profile (%)

B2B: 100%

B2C: 0%

Industries Served (%)

Pharma & Health Associations: 100%

Additional Information

- Nationwide coverage across 3,200+ clinics and pharmacies

- Long-standing clients with multi-year commitments

- Key partnerships with professional associations

- Resilient subscription model ensuring stable cash flow

- Lean operations: small HQ team, freelancers, and 40+ contracted field agents

- Strong growth outlook: Projected revenues of C$3.4M in FY2025 and C$4.35M in FY2026 with 42%+ EBITDA margins

- Expansion potential in digital, AI-led engagement, and specialty healthcare markets

The Process

Sign NDA
Thank you for signing our NDA, we're excited to share this information with you!

Review Materials
We'll share marketing materials about the seller's business for your review

Meet Our Team
We'll be speaking with potential buyers (you included) on behalf of our sellers to answer questions, discuss the fit and outline the process

Meet the Seller
We're here to introduce our sellers to potential buyers. These calls are an open format for buyers to ask questions about the business and for sellers to familiarise themselves with the potential buyer and the cultural fit for their team

Submit an LOI
Taking this opportunity to the next step, a buyer shares their proposed transaction structure and it is shared with the seller.

Due Diligence
The selected buyer now has access for a full analysis of the sellers' business to finalise the transaction.

Closing
All agreements are signed and funds are transferred. Congratulations!

Our most recent listings

Content Marketing | E-commerce

Premier National E-Commerce Content Agency with Tier-1 CPG Clients | $4M Revenue, $1.5M EBITDA, 80% Retainer Base

Located in the North East of the United States and established in 2017, this agency has quickly become a leading content creation partner within the e-commerce CPG sector. Over the…...

View listing
Public Relations

U.S.-Based Category-Leading PR & Communications Agency for Parenting and Lifestyle Brands

This established U.S.-based PR and communications agency has built a market-leading reputation as the go-to partner for parenting and lifestyle brands. With 14+ years of sector expertise, it specialises in…...

View listing
Lead Generation | Linkedin Marketing | Telemarketing

Tech-Enabled Sales Enablement Agency Specialising in Telemarketing & LinkedIn Outreach for Global Events and Media Brands

This lean, high-margin UK-based telemarketing and LinkedIn outreach agency has built a strong reputation as a go-to sales support partner for the global exhibitions, media, and membership sectors. Operating with…...

View listing
Experiential

UK-Based Large Format Visual Production & Print Agency Serving Leading Brands

A well-established, large-format print and branded visual production agency based in the UK, delivering high-impact campaigns for premium global brands across retail, sport, hospitality, experiential, and events. With over 20…...

View listing